ArticleTheranostics2020
UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 66 citations in OpenAlex.
- UCH-L1 down-regulates HER2 expression and increases lapatinib sensitivity by interacting with HSP90 in HER2-positive breast cancer.Genes & diseases · 2026Article
- Assessing the suitability of deubiquitylases as substrates for targeted protein degradation.Cell chemical biology · 2026Article
- Deubiquitinase UCH-L1 confers paclitaxel resistance via stabilizing PKM2 to promote glycolysis in triple-negative breast cancer.Cell death & disease · 2026Article
- PARK2-Mediated PGK1 Degradation Suppresses Partial Epithelial-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer.Oncology research · 2026Article
- Research progress of DUB enzyme in breast cancer.Clinical and experimental medicine · 2025Review
- Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha.Nature communications · 2025Article
- The revelation of UCHL1 in malignant epithelial cells of TNBC reinforcing cisplatin resistance by modulating ferroptosis based on single-cell transcriptome data.Journal of clinical biochemistry and nutrition · 2025Article
- Adipose stem cell exosomes, stimulated by pro-inflammatory factors, enhance immune evasion in triple-negative breast cancer by modulating the HDAC6/STAT3/PD-L1 pathway through the transporter UCHL1.Cancer cell international · 2024Article
- UCHL3 promotes hepatocellular carcinoma progression by stabilizing EEF1A1 through deubiquitination.Biology direct · 2024Article
- UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5.Breast cancer research : BCR · 2024Article
- Potential roles of UCH family deubiquitinases in tumorigenesis and chemical inhibitors developed against them.American journal of cancer research · 2024Review
- Article
- Recent advances in anti-inflammatory active components and action mechanisms of natural medicines.Inflammopharmacology · 2023Review
- Functionalized Gold Nanoparticles Suppress the Proliferation of Human Lung Alveolar Adenocarcinoma Cells by Deubiquitinating Enzymes Inhibition.ACS omega · 2023Article
- Stabilization of estrogen receptor α by USP37 contributes to the progression of breast cancer.Cancer science · 2023Article
- Ubiquitin C‑terminal hydrolase‑L1: A new cancer marker and therapeutic target with dual effects (Review).Oncology letters · 2023Review
- Ubiquitin C-terminal hydrolase L1 (UCHL1), a double-edged sword in mammalian oocyte maturation and spermatogenesis.Cell proliferation · 2023Review
- Review
- eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.Journal for immunotherapy of cancer · 2022Article
- Clinical Potential of miR-451 and miR-506 as a Prognostic Biomarker in Patients with Breast Cancer.Journal of healthcare engineering · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 2 countries.
Xi-Sha ChenXiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China.
Kuan-Song WangDepartment of Pathology, Xiangya hospital and Department of Pathology, School of Basic Medicine, Central South University, Changsha, 410078, China.
Wei GuoDepartment of Pathology, Xiangya hospital and Department of Pathology, School of Basic Medicine, Central South University, Changsha, 410078, China.
Lan-Ya LiXiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China.
Pian YuXiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China.
Xin-Yuan SunXiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China.
Hai-Yan WangXiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China.
Yi-Di GuanXiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China.
Yong-Guang TaoCancer Research Institute, School of Basic Medicine, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Central South University, Changsha, 410078, China.
Bo-Ni DingDepartment of Breast and Thyroid, The Third Xiangya Hospital, Central South University, Changsha, 410078, China.
Ming-Zhu YinDepartment of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Xing-Cong RenDepartment of Cancer Biology and Toxicology, College of Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
Yi ZhangDepartment of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China, 215000, China.
Ce-Shi ChenKey Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Collaborative Innovation Center for Cancer Medicine, Kunming, 650223, China.
Yuan-Chao YeDepartment of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, 52242,USA.
Jin-Ming YangDepartment of Cancer Biology and Toxicology, College of Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
Yan ChengXiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China.
Central South University · CNMarkey Cancer Center · USSoochow University · CNUniversity of Iowa · USUniversity of Kentucky · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsBreast NeoplasmsDown-RegulationDrug Resistance, NeoplasmErbB ReceptorsEstrogen AntagonistsEstrogen Receptor alphaFemaleFulvestrantHumansMiceMice, NudeTamoxifenUbiquitin ThiolesteraseUp-RegulationEGFR protein, humanErbB ReceptorsESR1 protein, humanEstrogen AntagonistsEstrogen Receptor alphaFulvestrantTamoxifenUbiquitin ThiolesteraseUCHL1 protein, humanEGFREndocrine therapyER-negative breast cancerEstrogen receptor αUbiquitin carboxyl terminal hydrolase-L1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.